Clinical Trial Update: Inhibition of Urinary Angiotensinogen and the Reduction of Blood Pressure by SGLT2 Inhibition in Patients With Type 2 Diabetes [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating SGLT2 inhibitors for reduction of blood pressure by inhibiting urinary angiotensinogen in patients with type 2 diabetes and hypertensio…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypertension
• Type 2 Diabetes Mellitus

Snippet

Sponsor: Tulane University School of Medicine | Conditions: Type 2 Diabetes, Hypertension | Phase 4 | Status: COMPLETED | Results posted: 2022-11-01